Clinical Trial Update: A Study of the Dose Proportionality of Extended Release Paliperidone [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating dose proportionality of extended-release paliperidone in schizophrenia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Invega ER (paliperidone extended-release)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED